Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 15;8(20):e013389.
doi: 10.1161/JAHA.119.013389. Epub 2019 Oct 12.

SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects

Carolyn S P Lam  1   2   3   4 , Chanchal Chandramouli  1 , Vineeta Ahooja  5 , Subodh Verma  6
Affiliations
Review

SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects

Carolyn S P Lam et al. J Am Heart Assoc. .
No abstract available

Keywords: SGLT‐2 inhibitors; heart failure; type 2 diabetes mellitus; unmet needs.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Key unmet needs in the management of HF.5, 6, 32, 33 ACE indicates angiotensin‐converting enzyme; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; RAAS, renin‐angiotensin‐aldosterone system.
Figure 2
Figure 2
Mechanistic rationale for investigating SGLT‐2 inhibitors in HF beyond T2D. CV indicates cardiovascular; HF, heart failure; SGLT‐2, sodium‐glucose cotransporter‐2; T2D, type 2 diabetes mellitus.
Figure 3
Figure 3
Ongoing trials of SGLT‐2 inhibitors in HF.104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114 *Dual SGLT‐1/SGLT‐2 receptor antagonist. EF indicates ejection fraction; LPLV, last patient last visit; SGLT‐2, sodium‐glucose co‐transporter‐2; T2D, type 2 diabetes mellitus.
See this image and copyright information in PMC

References

    1. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Pina IL, Trogdon JG. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6:606–619. - PMC - PubMed
    1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–1259. - PMC - PubMed
    1. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3:7–11. - PMC - PubMed
    1. Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2013;10:401–410. - PMC - PubMed
    1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez‐Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200. - PubMed

Publication types

Substances